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Abstract The endothelium has increasingly been recognized
as a smart barrier and a key regulator of blood flow in micro-
and macrovascular beds. Endothelial dysfunction marks a
stage of atherosclerosis and is an important prognostic marker
for cardiovascular disease. Yet, some people who tend to be
slim and physically active and with rather low blood pressure
show a propensity to respond to certain stimuli such as emo-
tional stress with endothelial-mediated vascular dysregulation
(Flammer syndrome). This leads to characteristic vascular
symptoms such as cold hands but also a risk for vascular-
mediated diseases such as normal-tension glaucoma. It is the
aim of this review to delineate the differences between
Flammer syndrome and its Bcounterpart^ endothelial dysfunc-
tion in the context of cardiovascular diseases.
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Introduction
The endothelium has increasingly been recognized as a smart
barrier and a key regulator of blood flow in micro- and
macrovascular circulation. Endothelial dysfunction is a key
mediator in the development of atherosclerosis and is present
long before atherosclerotic plaques or even cardiovascular
events. Endothelial dysfunction in this context can be
considered as the Brisk of the risk factors^ because it depicts
the sum of all known, but also hitherto unknown cardiovas-
cular risk factors together [1]. Once endothelial dysfunction is
present, it predisposes the vessel to vascular lesions, inflam-
mation, vasoconstriction, thrombosis, and finally plaque rup-
ture. Furthermore, it is an important prognostic marker for
cardiovascular events. Interestingly, cardiovascular-
protective drugs, healthy nutrition, and lifestyle changes all
ameliorate endothelial dysfunction.
On the other side, a dysfunctional endothelium must not
necessarily have a connection with atherosclerotic disease.
Blood supply to different organs or vascular beds is regulated
by the vascular endothelium. A dysfunctional endothelium
may in certain persons with a predisposition lead to an inad-
equate organ perfusion due to vascular dysregulation.
Affected persons may respond to certain stimuli, e.g., emo-
tional stress, with endothelial-mediated inadequate vascular
constriction or dilatation (Flammer syndrome), leading to
characteristic vascular symptoms such as cold hands or
vascular-mediated diseases such as normal-tension glaucoma.
It is the aim of this review to first discuss endothelial dys-
function from the cardiologist’s perspective and then to delin-
eate the differences between the Flammer syndrome and its
Bcounterpart^ endothelial dysfunction in the context of cardio-
vascular diseases.
What is endothelial function and how is blood flow
regulated?
The concept of cardiovascular pathophysiology over the
course of decades has been rewritten for several times by
new insights into the function of the endothelium. An organ
not easily recognized, this single layer of squamous cells in
constant contact with our blood covers an area equivalent to a
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soccer field. Penicillin Nobel laureate Lord Florey has con-
cluded in 1966 that his purely morphological investigations
[2] in this previously assumed mere Bsheet of nucleated
cellophane^ had left much to be desired.
Today, the endothelium is considered a smart barrier and a
key regulator of blood flow in micro- and macrovascular beds
modulated by paracrine, autocrine, and endocrine response to
mechanical and chemical stimuli (Fig. 1). Beyond vascular ho-
meostasis and vascular tone, it orchestrates diverse functions:
smooth muscle cell proliferation [3, 4], transendothelial leuko-
cyte diapedesis [5, 6], and thrombosis and thrombolysis [7].
Perfusion is determined by cardiac output and systemic and
local resistance. Locally, blood flow is the result of vascular
relaxation and contraction that is balanced by endothelium-
derived vasodilatative and vasoconstrictive factors. In impaired
function, the scale is tipped towards prevailing constrictive fac-
tors and/or downregulated vasodilatative factors. Among these
factors, one signal molecule stands out as hub and target of
many pathways and mechanisms: nitric oxide (NO).
Alfred Nobel invented dynamite, i.e., explosive nitroglyc-
erin kept in check because it is absorbed in porous kieselguhr.
Ironically, he refused to take nitroglycerin for his chest pain, as
he rejected the already common knowledge of his time that
nitroglycerin could ameliorate angina. It would take another
century until 1998 that a Nobel prize was awarded for the
discovery of NO’s role in endothelial function. Robert F.
Furchgott and colleagues [8] had observed that acetylcholine
dilated blood vessels only if the endothelium was intact. He
and Louis J. Ignarro identified the endothelium-derived relax-
ation factor as identical to NO in 1986/1987 [9]. This event
triggered a deluge of research about the first gaseous signal
molecule ever discovered.
It is important to understand the biochemical foundations
of NO for endothelial function. Nitric oxide synthase III
(eNOS, encoded in the NOS3 gene) dimerizes in the presence
of tetrahydrobiopterin as a cofactor. It exhibits a reductase and
an oxidase domain that are conformationally cross-linked after
calmodulin [10] binding. In this active conformation, eNOS
reduces oxygen on its heme group through an electron chain
of NADPH, FAD, and FMN to eventually insert it in L-
arginin’s guadino-group to form L-citrullin and NO. The
short-lived NO (5–10-s half-life) rapidly diffuses to the sur-
rounding smoothmuscle cells to signal via intracellular cGMP
[11] resulting in calcium-mediated relaxation, thus vasodila-
tion (Fig. 1). In absence of eNOS’ obligate cofactor
tetrahydrobiopterin or its substrate L-arginine (e.g., through
oxidative stress), eNOS uncouples to homodimers and instead
of NO produces reactive oxygen species (ROS) diminishing
NO, rapidly signaling through reactions with proteins and
transcription factors a state of distress [12–14].
An important counterweight in the vascular balance is cy-
clooxygenase (COX). Mostly COX1 and if expressed [15]
COX2 have a pivotal role in producing vasoconstrictive fac-
tors. COXs transform arachidonic acid into endoperoxides
and further into thromboxane A2 (TXA2) and prostaglandins
D2, E2, and/or F2α. Prostacyclin [16] through prostacyclin
Fig. 1 The endothelium actively sends relaxing/dilating and constrictive
signals to the smooth muscle cells. Three central pathways are outlined:
The constituent endothelial nitric oxide synthase (eNOS, NOS III) is
regulated by endocrine and paracrine effects such as endothelin-1 (ETR,
ET-1) and acetylcholine (ACh) as well as shear stress via pertussis toxin-
sensitive Gq/i pathways, calcium, and calmodulin. Nitric oxide (NO) sig-
nals relaxation, but uncoupling can lead to increased oxidative stress
(H2O2). The endothelial cells also evoke hyperpolarization of the cell
membrane of smooth muscle cells (endothelium-dependent hyperpolari-
zation factor (EDHF)). Cyclooxygenase 1 (COX) produces eicosanoids
that have in the case of prostacyclin (PGI2) relaxing effects through cyclic
AMP or constrictive effects particularly for thromboxane A2 (TXA2).
Angiotensin II (A II) has direct (by angiotensin receptor 1 (AT1)) or
indirect constrictive effects through ET-1
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synthase (CYP8A1) is, on the other hand, mainly a dilating
factor, a potent antiaggregant, and a direct antagonist to
thromboxane A2.
A not exclusively vasoregulatory function of NO is
thrombogenesis involving von Willebrand factor. Local pres-
ence of thrombin evokes protective NO release. Platelet re-
lease of serotonin and ADP in turn increase NO synthesis and
release in healthy endothelium to induce dilatation. Without a
functional endothelium, thrombus formation is mechanically
promoted by vasoconstriction by thromboxane A2 and effect
of serotonin directly on the smooth muscle cells.
Various chemical signals (Fig. 1) work in concert to orches-
trate contracting factors (e.g., metabolites of arachidonic acid,
angiotensin) and vasodilation (foremost regulation of NO bio-
availability, prostacyclin, endothelial hyperpolarization fac-
tor). Endothelin-1 (ET-1) is two-faced in this balance. Aminor
share is secreted intraluminally not exclusively by endothelial
cells (and particularly in the pulmonary [17] vascular bed). Its
primary function is para- and autocrine: On endothelial cells,
it induces NO generation through ETB1 receptors, whereas
directly acting on ETA and ETB2 receptors on smooth muscle
cells (by diffusion or when endothelium is stripped), it acts as
a vasoconstrictor about 100-fold more potent than noradrena-
line [18]. It modulates cardiac function and propels (or is a
marker of) hypertrophy, arrhythmia, chronic heart failure,
myocardial infarction, and hypertension with implications of
regulatory function for sympathetic innervation [19].
Shear stress, the frictional force generated by blood flow, is
a potent mechanical inductor of NO. The molecular mecha-
nisms are mainly calcium-independent [20] and involve post-
translational modification by phosphorylation of eNOS at reg-
ulatory sites [21], messenger RNA (mRNA) stabilization [22],
e.g., through heat shock protein 90 (hsp-90), and translocation
[23]. NO produced in response to shear stress triggers vascular
smooth muscle relaxation, inhibition of apoptosis [24], and
inhibition of thrombocyte or monocyte adhesion [25].
Repeated transient shear stress induces NOS3 (eNOS gene)
transcription and leads thus to chronically higher NO produc-
tion in response to stimuli. This is one explanation for the
beneficial effect of physical exercise [26, 27]. Shear stress is
also the key concept for testing endothelial dysfunction
in vivo.
How can we measure endothelial function?
A toolbox of measuring methods has been established for
research and to some extent for clinical practice. All of which
are based on the principle of endothelium-dependent dilata-
tion in response to hyperemia or pharmacological endothelial
stimuli (e.g., acetylcholine, bradykinin, serotonin; see Fig. 1).
Besides different advantages in technical ease, invasiveness,
and reliability, a major difference is whether macro- or
microvascular beds are intended to be examined. Biomarkers
such as ET-1, circulating endothelial microparticles, and pro-
genitor cells can be analyzed [28].
In 1986, Ludmer and colleagues [29] demonstrated endo-
thelial dysfunction for the first time in vivo. The authors cap-
tured epicardial coronary artery dilatation after acetylcholine
intracoronary infusion by quantitative coronary angiography
in healthy coronaries with intact endothelium. Interestingly, in
atherosclerotic arteries, they noticed the opposite effect, vaso-
constriction. These findings laid the groundwork to under-
stand the pathogenesis of atherosclerosis and widened the
view from structure to function.
Several other techniques employ invasive quantitative cor-
onary angiography or intravascular ultrasound with exercise
[30] or mental stress (calculating) [31] as it allows for imme-
diate observation of a clinically important vasculature. A test
that relies on sympathetic mediation for NO release is the cold
pressor test: A subject submerges her hand for 2 min in ice
water. In healthy subjects, α 2-adrenoceptor-dependent vaso-
dilatation as seen, e.g., in quantitative coronary angiography
will prevail overα 1-adrenoceptor-mediated constriction (vice
versa in dysfunctional endothelium) [32, 33].
In 1992, Science proclaimed NO Bmolecule of the year^
[34] on a dedicated title. This very year, the first non-invasive
method to assess endothelial function was published [35] by
Celermajer and colleagues. The brachial artery response to
shear stress is measured by ultrasound as surrogate for the
epicardial coronary arteries, an association later confirmed to
be correlated [36]. Flow-mediated dilatation (FMD) is mea-
sured sonographically as peak percent dilatation from brachial
conduit artery baseline diameter. The measurement is derived
from 10-min continuous 2D mode imaging after blood flow
had been restricted by inflating an upper arm cuff for 5 min
[37] above systolic blood pressure. Hyperemic shear stress is
induced after sudden cuff deflation (Fig. 2). To ascertain mea-
surement of endothelial-dependent function, usually the dila-
tation of the artery in response to a dose of glycerol trinitrate is
measured [38, 39].
FMD is probably the most popular method to measure
endothelial dysfunction due to its non-invasiveness and corre-
lation with coronary vasoreactivity [40], as well as being
mainly NO-dependent [39] (though not exclusively [41]).
Strain-gauge venous plethysmography of the forearm circula-
tion resembles FMD but is semi-invasive. In contrast, phar-
macological agents (e.g., acetylcholine) are administered by
intra-arterial infusion in a dose-dependent manner to test
vasoreactivity of the brachial artery. The other forearm serves
as internal control due to minimal systemic effect of the infu-
sion [42]. Generally, FMD and plethysmography are better
suited for serial or longitudinal studies than between-group
testing due to interindividual variability [43].
The microvasculature serves directly to regulate blood flow
for tissue metabolic needs and is responsible for 70% of the
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systemic vascular resistance. Capillary venular interactions
can become relevant, myogenic regulation less so, and endo-
thelial anatomy differs in vascular beds (e.g., fenestration,
innervation). It comes to no surprise that in two large cross-
sectional cohort studies [44, 45], non-invasive FMD of the
brachial conduit artery and digital vascular dysfunction only
modestly correlated and differed in their relation to traditional
cardiovascular risk factors [46]. Thus, they might reflect dif-
ferent aspects of vascular biology [47].
In peripheral pneumatic arterial tonometry (PAT), digital
pulse wave amplitude at baseline (preocclusion) and changes
during reactive hyperemia are recorded and the reactive
hyperemia-PAT index (RHI) is calculated as a standardized
post-/preocclusion ratio [47, 48]. RHI is correlated with coro-
nary [49] endothelial dysfunction. The main advantages of the
EndoPAT analysis are that interrater and test-retest reliability
are high while being non-invasive [48]. The peripheral vascu-
lar bed at distal limbs is the major site of sympathetic α-
adrenergic vasoconstrictor activity [50, 51]. The use of the
specific NO antagonist L-NMMA has defined the contribution
of NO to these vasomotor responses: Approximately 60% of
the PAT response is mediated by NO release [52, 53]; the rest
is probably mediated by the autonomous nervous system.
The eye as a direct window to vascular function has an
appeal beyond structural assessment [54]. Static and dynamic
retinal vessel analyses (RVA) are unique and elegant in several
ways. The retina is the only vascular bed of which we are sure
that responses to stimuli are independent of the autonomic
innervation. In addition, due to the blood-retinal-barrier, most
circulating vasoactive molecules do not get direct access to
smooth muscle cells. In other words, it is the ideal place to
study the function of the vascular endothelium.
Static RVA (Fig. 3) can be reproducibly and automatically
performed on routine fundus photographs [56]: arteriovenous
ratio is measured (semi-)automatically as the ratio of equiva-
lents of arteriolar and venular diameters in a 0.5–1 optic disc
diameter distance around the optic nerve head [57]. The small-
er and larger diameters are approximately normally distributed
which allows for calculation of the equivalents according to
Parr and Hubbard [58–60]. The ratio is a cardiovascular risk
factor and predictor of long-term outcome [61].
Dynamic RVA (DVA) induces shear stress through flicker
light stimulation. The retina is filmed by a charge-coupled
camera to determine baseline diameters and while episodes
of optoelectric diffuse flicker light alternate with 80-s constant
illumination phases. Uniquely, shear stress is not induced by
reperfusion reactive hyperemia but functional hyperemia by
neurovascular coupling. The exact pathways involved in
neuro-glia-vascular coupling are not fully understood.
Likely, oxygen demand in response to flicker light increases
[62] and stimulated neurons signal a calcium concentration
surge in Müller glia that release vasodilatory prostaglandin
E2, NO, and epoxyeicosatrienoic acids [63, 64]. The
gliovascular unit, thus, relaxes the smallest arteriolar walls.
Due to then less resistant smallest vessels, blood starts flowing
faster, which increases shear stress in bigger arteriolar seg-
ments. An intact retinal arteriolar endothelium responds to
the shear stress by vasodilatation to keep shear stress constant
(Fig. 4). NO has been confirmed to play a major role in retinal
flicker-induced vasodilatation [68]. However, it cannot be ex-
cluded that a disturbed or reduced neurovascular coupling
itself is involved as well: neurovascular coupling depends on
the function of the astrocytes [69] and these astrocytes are
particularly often Bactivated^ (and therefore altered in their
function) in subjects with Flammer syndrome [70].
Endothelial dysfunction—a hallmark
of cardiovascular disease
Loss of NO bioavailability is the salient feature of a dysfunc-
tional endothelium, which in turn is the sentinel of systemic or
focal vascular disease. Presence of classic cardiovascular risk
factors is associated with deteriorated endothelial function, [1]
and conversely, risk factor modification is connected with its
improvement. That a considerable number of patients at risk
cannot be identified based on conventional risk factors [71] as
incorporated in the Framingham risk score prompted the quest
for other relevant risk predictors.
The prognostic value of FMD as surrogate for endothelial
function has first been shown for hypertension. Modena and
colleagues [72] measured how FMD changed in 400
Fig. 2 Method of flow-mediated dilation to measure endothelial dys-
function. The graph shows the diameter at baseline (A), during 5 min of
cuff inflation (B), and the reactive hyperemic vasodilation with initial
vasoconstriction (C). The diameters were measured on a longitudinal
section of the brachial conduit artery in 2D mode. The measurements
are automatically computed by FMD Studio (Quipu srl, Pisa)
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postmenopausal women before and 6 months after establish-
ment of optimal blood pressure control. Women responding to
therapy with >10% FMD improvement had significantly few-
er events during 67month follow-up. In theMultiethnic Study
of Atherosclerosis, healthy elderly (>72 years) had a signifi-
cantly longer event-free survival over a 5-year follow-up if
they initially had normal endothelial function [73].
The Atherosclerosis Risk in Communities (ARIC) study
generated much insight in the association of microvascular
retinal endothelial dysfunction and systemic risks and showed
predictive value for static RVA [74–77]. Over 16 years of
follow-up in 10,470 initially healthy individuals, it was shown
that narrower retinal arterioles and wider venules confer a
significant risk for ischemic stroke and all-cause mortality
[61].
The etiology of atherosclerosis is a complex process that
starts long before structural manifestation and their debilitat-





Fig. 4 Description of dynamic retinal vessel analysis. aVideo automated
tracing of marked arteriole (red) and venula (blue) for tracing during
flicker light. b Relative diameter over time: baseline, dilatation due to
flicker light (during gray-shaded area) expressed as relative diameter
compared to baseline (100%), and return to baseline. Of note, normal
values are in a range of 2–12% and a 19% increment in radius will
double the volume flow rate according to Poiseuille’s law. Also
baseline amplitude, slope, and postdilatative contraction can be
measured [65]. Importantly, both arterial and venous (c) dilatative
response have been linked to disease [66, 67]. Green line: normal
range, red/blue lines: normal flicker-induced arterial/venous dilatation,
dark gray line: pathological, blunted response to flicker light
AVR: 0.85
Fig. 3 Static retinal vessel analysis by semi-automatically tracing all
vessels in a range of 0.5 to 1 its diameter around the optic disc. By
dividing the sum of diameters of arterioles and venules, the arteriovenous
ratio is calculated. The BAtherosclerosis in Community Study^ (ARIC)
has widely validated association of the arteriovenous ratio with cardio-
vascular risk and outcome. Normal values are age-dependent and lie in a
range of 0.75–1 [55]
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atherosclerotic process already in early adulthood and even
childhood [35]. Dyslipidemia is a major factor in development
and progression of atherosclerosis. Oxidated LDL (ox-LDL)
downregulates eNOS/NOS3 expression [3]. Endothelin
through ET-B receptor augments ox-LDL uptake in plaques
and upregulates lectin-like ox-LDL receptor-1 mRNA that
facilitates ox-LDL internalization [78, 79]. A process called
Buncoupling^ of eNOS is initiated triggering the production of
superoxide anions (O2
−) [80, 81]. This potent free radical is a
messenger molecule and, in a vicious cycle, propels the pro-
duction of ox-LDL. The thus impaired endothelial cell signals
proliferation to smooth muscle cells with subsequent extracel-
lular matrix changes in the intima compartment. The inflam-
matory process starts with the attraction of monocytes.
Transendothelial migration of monocytes and subsequent
transformation in foam cells are the result. Importantly, expo-
sition to undisturbed laminar flow enhances NO-forming ca-
pacity and is strongly protective [82].
A fundamental pathomechanistic insight can be gained by
scrutiny of the endothelium. Takotsubo syndrome [83] often
presents with symptoms of an acute coronary syndrome but is
typically [84] characterized by apical ballooning of the heart
that restitutes within weeks. No or no relevant stenoses of the
epicardial coronaries are found, and biomarkers of cardiacmus-
cle necrosis like troponin are only slightly elevated. In approx-
imately two thirds of all cases, an intense (positive [85] or
negative) emotional or physical stress precedes the transient,
reversible, systolic dysfunction of the left ventricle (Bbroken
heart syndrome^). About 90% of Takotsubo cardiopathy pa-
tients are female [86]. As evidently epicardial coronary artery
stenosis is no explanation, hypotheses for the etiopathology of
Takotsubo cardiopathy soon focused on transient vascular
spasm, microvascular functional impairment, and autonomous
nervous dysfunction. These hypotheses were supported by a
recent study: FMD was found to be significantly reduced in
Takotsubo patients in a stable phase whereas sympathetic ac-
tivity in response to stress tended to be increased [43].
Endothelial dysfunction plays a role not only as a marker of
disease progression but, conversely, as a response marker to
interventions. Dietary interventions [4], e.g., with flavonoids
such as in dark chocolate [87, 88], led to improved endothelial
function, as did physical exercise [74, 89–91]. Quantification
of endothelial dysfunction can predict therapeutic success of
pharmacologic intervention, too. Angiotensin-converting en-
zyme inhibitors (ACE-I) showed clear improvement of endo-
thelial dysfunction in several modalities [92–94]. Additional
improvement could be shown for add-on spironolactone in
chronic heart failure patients [95]. Calcium channel blockers
are vasodilators acting on L-type calcium channels in vascular
smooth muscle cells. Some calcium channel blockers activate
endothelial NO synthase or have antioxidative properties, thus
increasing NO bioavailability. Nifedipine improved coronary
endothelial function in stable coronary artery disease patients
in the ENCORE II study [96]. Endothelial dysfunction, thus,
continues to be a relevant mechanistic explanation variable in
recent and future intervention studies.
Endothelial dysregulation in Flammer syndrome
At first glimpse, the symptoms constituting Flammer syn-
drome (FS, primary vascular dysregulation) do not seem to
fit together and lack a common pathophysiologic basis.
Historically, the first two dots of FS’s diverse symptoms were
connected by the observation that some glaucoma patients had
conspicuously cold hands [97, 98] (please see article by to
Prof. J. Flammer and Dr. K. Konieczka’s in this volume for
a scientific detective story of the history and findings in
Flammer syndrome).
Crucially, people with FS seem less prone to atherosclero-
sis but exhibit signs of endothelial dysfunction. Endothelial
dysfunction appears to take on a different role in vascular
dysregulation than in atherosclerotic etiology. The phenotype
of FS is already suggestive of protective factors against ath-
erosclerosis: People with FS tend to be more physically active
and slimmer than patients with atherosclerosis particularly
with metabolic syndrome [99]. As an overall principle under-
lying FS, an increased sensitivity to emotional or physical
stress emerges as trigger of varying blood perfusion with tran-
sient malsupply [100]. This, in turn, causes oxidative stress
and impaired endothelial function [101].
Identification of individuals with FS may be clinically rel-
evant as systemic vascular dysregulation has been associated
with several ocular diseases [102], including glaucoma
[103–110], central serous chorioretinopathy [111], and central
retinal vein occlusion. The role of the endothelium as major
pathomechanistic red line connects many dots that outline a
sketch of FS. Particularly, ET-1 (ET-1), autonomic dysfunc-
tion, and oxidative stress may link the differing vascular beds
involved in FS. Consequently, FS may inflict heart [109] and
brain [112, 113] as a systemic state.
Microvascular regulation and its failure may be a more
crucial aspect to FS than macrovascular dysfunction that is
also commonly found in atherosclerotic patients. Not only
atherosclerosis but also microvascular dysfunction affects
the heart. The link to Takotsubo syndrome or microvascular
angina may yet to be substantiated, but evidence for transient
hypoperfusion of the heart has been described [114, 115]. In
24-h EKG recordings of glaucoma patients, transient especial-
ly nocturnal ST elevations have been recorded, a typical sign
of cardiac ischemia.
It has been hypothesized that an imbalance of ET-1 and
endothelial NO due to impaired endothelium is a crucial
pathomechanism in FS disturbing ocular perfusion [101].
The importance of ET-1 (or circulatory vasoconstrictors)
arises from the extraordinary blood supply of and around the
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optic nerve head (ONH): superficial layers receive blood from
central retinal artery branches with a blood-brain barrier. The
prelaminar region (anterior to the lamina cribrosa), on the
other hand, is a pure capillary circulation supplied by choroi-
dal artery branches and the short posterior ciliary arteries,
which do not possess a blood-brain barrier. The retinal vessels
completely lack autonomic innervation. The regulators of the
size of retinal vessels are, thus, the vascular endothelial cells.
An effect from systemic ET-1 is likely if the blood-brain bar-
rier is disrupted [66, 116]. The blood-brain barrier in the ONH
is incomplete [117]. ET-1 locally produced in response to
hypoxia could exert vasoconstrictive effects on and around
the ONH by local spillover despite intact endothelium. One
reason for this is that molecules can freely diffuse from the
choroid into the ONH; another is the cross talk between arter-
ies and veins in areas where they share a common adventitia.
In normal-tension glaucoma (NTG), for which FS is an
important risk factor [97, 98], circulating ET-1 is elevated
and even more so than in high-tension glaucoma (HTG)
[118]. ET-1, on the other hand, reduces ocular blood flow
but does not interfere with autoregulation. In FS, the capacity
to avoid too little or too much perfusion is fundamentally
disturbed. The glaucoma pathomechanism as explained by
impaired autoregulation in FS is as follows: transient hypoxia
leads to oxidative stress that further impairs not only endothe-
lium but the ONH. The ONH damage explains the bundle-
shaped damage and loss of retinal ganglion cells and their
axons [107]. Hypoxia (e.g., by varying blood supply in FS)
in the retina induces ET-1 production mainly by unoxidized
hypoxia-induced transcription factor 1α (HIF-1α) that serves
as a Bmaster switch^ [119] that activates (among others) tran-
scription of ET-1 and VEGF [120].
Autonomic dysfunction is suggested by the observation of
cold extremities (hands, feet, cornea) exacerbated by cold or
emotional upset [97, 116]. Cold acra have been found in FS
similar to Raynaud’s phenomenon (CREST) or even
Raynaud’s disease, yet less pronounced [98]. The role of en-
dothelial dysfunction in primary and secondary Raynaud’s
phenomenon has been demonstrated with evidence from var-
ious modalities including autonomic nervous stress tests like
the cold pressor test [121–125]. It may be regarded a hetero-
geneous syndrome involving endothelial dysfunction as a key
player but not every form entails a propensity for atheroscle-
rosis. Which pathway contributes most to malicious vasocon-
striction in Raynaud’s disease remains open.
Conclusion: two endotheliopathies, two collectives
at risk
Endothelial dysfunction is classically regarded as the first
phase of atherosclerosis. Not only does it contribute to athero-
genesis but it serves as a measurable surrogate marker. Much
evidence has been gathered that it marks atherosclerotic pro-
gression and that its role as a marker holds true also in the
reverse direction: Lifestyle changes like physical activity, di-
etary intervention, and drugs such as ACE inhibitors measur-
ably improve endothelial dysfunction. Outcome studies be it
in the realm of prevention medicine or pharmacotherapeutic
interventions have established the association of ameliorated
endothelial dysfunction with improved hard endpoints in mor-
bidity and mortality.
Quite different facets of the endothelium’s important role in
vascular health become apparent in FS. One concerns a core
role particularly of the microvasculature: perfusion. Varying
blood flow ensuing transient malperfusion is a risk factor for
many ocular and other diseases. Increased reactivity to stimuli
such as cold and emotional stress underlies, thus, a complex
phenotype at heightened risk. The FS phenotype in many re-
spects directly contrasts the typical patient with endothelial dys-
function in atherosclerosis (cf. Fig. 7 in Flammer, Konieczka:
BThe discovery of the Flammer syndrome^ in this volume).
Classically, endothelial dysfunction has been regarded as an
integrative measure of cardiovascular risk comprising other tra-
ditional factors such as hypertension and metabolic syndrome,
the integral of all risk factors. FS challenges our view in the
presence of endothelial dysfunction in a collective that is dia-
metrically opposed to the typical patient at risk for cardiovas-
cular events: active, slim, normo- or hypotensive, and less
prone to metabolic syndrome [126]. Is too much of good bad?
Understanding of endothelial dysfunction of small vessels
aids to connect symptoms and signs that are not obviously
related, at first sight. Many areas are yet to be explored, e.g.,
the contribution of metabolic processes as well as the role of
genetic and epigenetic factors in either of the two different
endotheliopathies. Many open questions warrant further stud-
ies to help delineate FS, identify FS individuals, and ideally
enable us to offer preventive interventions to avoid sequelae
and ameliorate symptoms.
This article, thus, conforms with the PPPM principles of
preventive measures and patient stratification stated in the
BEPMAWhite Paper^ [127].
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